EuroAPI EuroAPI

X
[{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immunocore"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cancer Research"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Amphista Therapeutics"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Valo Therapeutics"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Amphista Therapeutics"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Microbiotica"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"The Institute of Cancer Research"},{"orgOrder":0,"company":"Gaeta Therapeutics","sponsor":"Oncorus","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"$0.2 million","newsHeadline":"Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics Ltd. for Use of Locally Delivered Interleukin-12 (IL-12) via Oncolytic Viral Expression in Combination with Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Gaeta Therapeutics"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus\u2019 Proprietary Safety Switch System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Autolus Therapeutics"},{"orgOrder":0,"company":"ONI","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONI and the University of Pennsylvania Start Research Collaboration to Identify Unique Biomarkers and Characteristics to Guide Next Generation CAR-T Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"ONI"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Exercises Option To License Proprietary Targeting Technology From Autolus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Autolus Therapeutics"},{"orgOrder":0,"company":"Tillomed Laboratories Ltd","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Completes Major Product Acquisition from Tillomed Spain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tillomed Laboratories Ltd"},{"orgOrder":0,"company":"Thor Medical","sponsor":"Nordic Nanovector","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nordic Nanovector Announces Agreement to Acquire Thor Medical, an Emerging Producer of Alpha-emitters for Radiopharmaceuticals to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Thor Medical"}]

Find Novel Oncology Drugs in Clinical Development in UNITED KINGDOM

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.

            Lead Product(s): Radioimmunoconjugate-based Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Nordic Nanovector

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Zentiva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This follows an original agreement with Moderna, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.

            Lead Product(s): mRNA-based Therapeutic

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            ONI

            Contact Supplier
            • Deals

            Details:

            The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes.

            Lead Product(s): CAR-T Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: University of Pennsylvania

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Autolus will receive payment for access to the RQR8 safety switch for the initial set of cell therapy programs with the potential for near term option exercise fees and development milestone payments.

            Lead Product(s): CAR-T Cell Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the licensing agreement with Gaeta Therapeutics, Oncorus will advance ONCR-177 as a potential new therapeutic option for cancer patients, including in combination with pembrolizumab and locally delivered Interleukin-12 (IL-12) via oncolytic viral expression.

            Lead Product(s): Interleukin-12 Expressing Oncolytic Virus,Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Oncorus

            Deal Size: $7.7 million Upfront Cash: $0.2 million

            Deal Type: Licensing Agreement November 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.

            Lead Product(s): Daratumumab

            Therapeutic Area: Oncology Product Name: Darzalex

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.

            Lead Product(s): Foralumab,CAR-T Therapy

            Therapeutic Area: Oncology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration is based on clinical studies conducted by CUH that evaluate immune checkpoint inhibitor drug response in cancer patients, combined with Microbiotica’s unrivalled microbiome profiling and analysis capability.

            Lead Product(s): Live bacterial therapeutics,Nivolumab,Ipilimumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cancer Research UK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY